MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci (GBS), which is responsible for 50% of life-threatening infections in new-born.
If you can't find it here or have feedback to our website, please do not hesitate to contact email@example.com or 28895854
Copyright 2013 Danskbiotek. All rights reserved.
created by: Mastafu Design